These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36147351)

  • 1. Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database.
    Shu Y; Zhang Q; He X; Liu Y; Wu P; Chen L
    Front Pharmacol; 2022; 13():990241. PubMed ID: 36147351
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system.
    Arabyat RM; Raisch DW; McKoy JM; Bennett CL
    Expert Opin Drug Saf; 2015; 14(11):1653-60. PubMed ID: 26393387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between tendon ruptures and use of fluoroquinolone, and other oral antibiotics: a 10-year retrospective study of 1 million US senior Medicare beneficiaries.
    Baik S; Lau J; Huser V; McDonald CJ
    BMJ Open; 2020 Dec; 10(12):e034844. PubMed ID: 33371012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system.
    Meng L; Huang J; Jia Y; Huang H; Qiu F; Sun S
    Int J Clin Pract; 2019 May; 73(5):e13331. PubMed ID: 30809871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis.
    Ali AK
    Ann Epidemiol; 2014 Apr; 24(4):279-85. PubMed ID: 24472364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders.
    Huruba M; Farcas A; Leucuta DC; Bucsa C; Sipos M; Mogosan C
    Sci Rep; 2021 Jul; 11(1):14375. PubMed ID: 34257376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?
    Bidell MR; Lodise TP
    Pharmacotherapy; 2016 Jun; 36(6):679-93. PubMed ID: 27138564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data mining of the public version of the FDA Adverse Event Reporting System.
    Sakaeda T; Tamon A; Kadoyama K; Okuno Y
    Int J Med Sci; 2013; 10(7):796-803. PubMed ID: 23794943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin-induced bilateral Achilles tendonitis.
    Lewis JR; Gums JG; Dickensheets DL
    Ann Pharmacother; 1999; 33(7-8):792-5. PubMed ID: 10466906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study.
    Morales DR; Slattery J; Pacurariu A; Pinheiro L; McGettigan P; Kurz X
    Clin Drug Investig; 2019 Feb; 39(2):205-213. PubMed ID: 30465300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preventable, life-altering case of fluoroquinolone-associated tendonitis.
    Wildermuth A; Holmes M
    JAAPA; 2022 Nov; 35(11):33-36. PubMed ID: 36282576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolone use and the change in incidence of tendon ruptures in the Netherlands.
    van der Linden PD; Nab HW; Simonian S; Stricker BH; Leufkens HG; Herings RM
    Pharm World Sci; 2001 Jun; 23(3):89-92. PubMed ID: 11468881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study.
    Sode J; Obel N; Hallas J; Lassen A
    Eur J Clin Pharmacol; 2007 May; 63(5):499-503. PubMed ID: 17334751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.
    Hu Y; Bai Z; Tang Y; Liu R; Zhao B; Gong J; Mei D
    J Diabetes Res; 2020; 2020():3695101. PubMed ID: 32695827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triceps Ruptures After Fluoroquinolone Antibiotics: A Report of 2 Cases.
    Shybut TB; Puckett ER
    Sports Health; 2017; 9(5):474-476. PubMed ID: 28610536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.
    Sakaeda T; Kadoyama K; Minami K; Okuno Y
    Int J Med Sci; 2014; 11(5):461-5. PubMed ID: 24688309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study.
    Pozsgai K; Szűcs G; Kőnig-Péter A; Balázs O; Vajda P; Botz L; Vida RG
    Front Pharmacol; 2022; 13():964399. PubMed ID: 36147337
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.
    Cao M; Pan C; Tian Y; Wang L; Zhao Z; Zhu B
    Int J Clin Pharm; 2023 Jun; 45(3):689-697. PubMed ID: 36977858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.